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Abstract
I In nt tr ro od du uc ct ti io on n: : Use of biological therapies may reduce or delay the surgical pro-
cedures in patients with inflammatory bowel disease (IBD). The aim of this meta-
analysis and systematic review was to determine the impact of pre-operative
infliximab (IFX) use on the rate of surgical interventions in patients with IBD
and also the effect of preoperative IFX therapy on post-surgical complications.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   Literature was searched for studies that investigated
the efficacy of IFX on the rate of colectomy and post-operative complications/side
effects in patients with IBD between 1966 and February 2011.
R Re es su ul lt ts s: : Twelve articles were included in the meta-analysis. In comparison to
control groups, patients who received IFX had a relative risk (RR) of 1.17 
(p = 0.65) for the rate of colectomy, odds ratio of 3.34 (p = 0.09) in seven obser-
vational studies and RR of 0.74 (p = 0.79) in clinical trials for mortality. Sum-
mary RR of hospitalization was 0.61 (p = 0.005). Infections and anastomotic
leak, pouch-related complications, sepsis and thrombotic events were more
common in the patients under IFX therapy but post-operational hospitalization
was lower. The patients with IBD who were under IFX therapy were most of the
times refractive to other therapies and their disease was more severe. 
C Co on nc cl lu us si io on ns s: : Although IFX does not decrease the rate of colectomy in patients
with IBD, it would not increase most of the post-operational side effects in the
patients. 
K Ke ey y   w wo or rd ds s: :   systematic review, meta-analysis, infliximab, anti-TNF, colectomy, post-
operative complications, inflammatory bowel disease.
Introduction 
Inflammatory bowel disease (IBD) is characterized by severe and pro-
gressive inflammation in the gastrointestinal (GI) tract, and includes the
two main clinicopathological subtypes of ulcerative colitis (UC) and Crohn's
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disease (CD). Various medical treatments have been
shown to be effective in management of IBD [1, 2].
Current  medical  treatments  for  IBD  generally
include sulfasalazine [3], 5-aminosalicylates [4], cor-
ticosteroids, immunomodulators [5, 6] and biolog-
ical therapy [7]. Even with optimized medical ther-
apy, 30-40% of patients with UC and 70-80% of
patients with CD may need surgery at some point
during the course of their disease [8, 9]. Although
surgery may lead to relief of symptoms and with-
drawal of potentially toxic medication, several com-
plications including anastomosis leakage, pelvic
abscess, wound infection, small bowel obstruction,
bleeding, and faecal incontinence may occur post-
operatively [9]. Pre-operative use of immunomod-
ulators and biological agents such as infliximab
(IFX) by suppression of the immune response poten-
tially increases the risk for postoperative infectious
complications [9, 10]. Increase in postoperative
infection by other immunomodulators such as glu-
cocorticoids and tacrolimus has been clearly shown
[10]. On the other hand, there is clinical evidence
that the use of IFX has reduced or delayed surgical
interventions in IBD patients [11, 12]. A previous
meta-analysis of the effect of IFX on short-term
post-operative complications in patients with UC
has demonstrated that short-term complications
were increased by use of IFX but infectious com-
plications and non-infectious complications were
not significantly increased separately [13]. In the
previous meta-analysis, five studies, published
between 1966 and September 2009, were includ-
ed and the effect of IFX on the rate of colectomy
was not analysed. 
The aim of this meta-analysis and systematic
review was to determine the impact of pre-opera-
tive IFX use on the rate of colectomy in patients with
IBD. We also intended to evaluate the effect of pre-
operative IFX therapy on surgical complications.
Material and methods
D Da at ta a   s so ou ur rc ce es s   
PubMed, Scopus, Web of Science, and Cochrane
Central Register of Controlled Trials were searched
for studies that investigated the efficacy of IFX on
the rate of colectomy and post-operative compli-
cations/side effects in patients with IBD. Data were
collected from 1966 to February 2011. The search
terms were “ulcerative colitis” and “Crohn” and
“infliximab” and “colectomy” and also their abbre-
viations were applied. The terms “surgery” and
“operation” and “IBD” were alternative keywords
for additional relevant articles. For PubMed, all rel-
evant MeSH terms were used. The final queries
were validated by manual review and matching
results. The reference lists from retrieved articles
were also evaluated to make sure all applicable
studies were included. The conference proceedings
were also searched. The key outcome of interest
was rate of colectomy and post-surgical adverse
events.
S St tu ud dy y   s se el le ec ct ti io on n
Studies that investigated the effectiveness and
influence of IFX on the rate of colectomy and/or
post-operative adverse events in patients with IBD
were considered. Operational procedures on side
effects such as fistuloplasty were not the outcome
of interest and they were excluded. Three review-
ers independently reviewed the title and abstract
of each article to eliminate duplicates, reviews, case
studies, trials that did not have institutional review
board approval and uncontrolled trials and those
published in languages other than English. Studies
which were clinical trials, cohorts and case matched
were included. Disagreements between reviewers
were resolved by consensus. Data on patients’ char-
acteristics, therapeutic regimens, dosage, sample
size, trial duration, and outcome measures were
extracted. 
A As ss se es ss sm me en nt t   o of f   t tr ri ia al l   q qu ua al li it ty y
The methodological quality of the included clin-
ical trials was evaluated using the Jadad score,
which assesses the descriptions of randomization,
blinding, and dropouts (withdrawals) in the trials
[14] (Table I), using the following dichotomized
parameters  (yes  =  1;  no  =  0):  randomization,
whether randomization was described appropri-
ately, double-blinding, whether double blinding was
described appropriately, and whether dropouts
(withdrawals) were described. The overall Jadad
score ranged from 0 to 5 points (score ≤ 2 low qual-
ity; ≥ 3 high quality).
S St ta at ti is st ti ic ca al l   a an na al ly ys si is s
Data from selected studies were extracted into
2 ￗ 2 tables. All included studies were weighted and
pooled. Data were analysed using StatsDirect ver-
sion 2.7.8. Odds ratio (OR) and 95% confidence
intervals (95% CI) were calculated using the Man-
tel-Haenszel and Der Simonian-Laird methods. The
Cochran Q test was used to test heterogeneity. The
event rate in the experimental (intervention) group
against the event rate in the control group was cal-
culated using L'Abbe plot as an aid to explore the
heterogeneity of effect estimates. Funnel plot analy-
sis was used as a publication bias indicator.
Results
The electronic searches yielded 664 items; 113
from PubMed, 17 from Cochrane Central, 51 from
Web of Science, and 483 from Scopus. Of these, 14
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articles were scrutinized in full text. Two reports
were considered ineligible. The included studies
comprised  3  randomized  clinical  trials  (RCTs), 
8 cohort, and one case-matched retrospective study.
In RCTs, 818 patients with UC were randomized to
receive IFX or placebo [12, 15, 16]. Cohort studies
represented 1915 patients, of whom 336 were treat-
ed with IFX [9-11, 17-21]. In one case-matched ret-
rospective study, 46 out of 92 patients were treat-
ed with IFX [22] (Table II and Figure 1).
E Ef ff fe ec ct ti iv ve en ne es ss s   o of f   i in nf fl li ix xi im ma ab b   c co om mp pa ar re ed d   
t to o   p pl la ac ce eb bo o   i in n   c co ol le ec ct to om my y   i in n   p pa at ti ie en nt ts s   w wi it th h
u ul lc ce er ra at ti iv ve e   c co ol li it ti is s
The summary RR for colectomy in 3 RCTs [12, 15,
16] was 1.17 with a 95% CI of 0.6-2.28 and a non-
significant RR (p = 0.65, Figure 2 A). The Cochrane
Q test for heterogeneity indicated that the studies
are heterogeneous (p = 0.02, Figure 2 B) and could
not be combined. Thus the random effects for indi-
vidual and summary of RR was applied. Regression
of normalized effect vs. precision for all included
studies for colectomy among IFX vs. placebo ther-
apy could not be calculated because of too few
included studies.
P Po os st t- -c co ol le ec ct to om my y   c co om mp pl li ic ca at ti io on ns s   i in n   p pa at ti ie en nt ts s   w wh ho o
r re ec ce ei iv ve ed d   I IF FX X   c co om mp pa ar re ed d   t to o   t th ho os se e   w wh ho o   d di id d   n no ot t   
M Mo or rt ta al li it ty y   
Summary OR of mortality in seven observational
studies [9-11, 17, 18, 21, 22] was 3.34 with a 95% CI
of  0.94-11.86,  a non-significant  OR  (p  =  0.09, 
Figure 3 A-a). The Cochrane Q test for heterogene-
ity indicated that the studies are homogeneous 
(p = 0.97, Figure 3 A-b) and could be combined;
thus the fixed effects for individual and summary
of OR was applied. Regression of normalized effect
vs. precision for all included studies for mortality
among IFX vs. placebo therapy was –0.75 (95% CI
= –2.94 to 1.45, p = 0.42) and Kendall’s test on stan-
dardized effect vs. variance indicated tau = –0.14,
p = 0.56 (Figure 3 C).
Summary RR of mortality in 3 RCTs [12, 15, 16]
was 0.74 with a 95% CI of 0.08-6.83, a non-signifi-
cant RR (p = 0.79, Figure 3 B-a). The Cochrane Q
test for heterogeneity indicated that the studies are
homogeneous (p = 0.97, Figure 3 B-b) and could be
combined; thus the fixed effects for individual and
summary of RR was applied. Regression of nor-
malized effect vs. precision for all included studies
for mortality among IFX vs. placebo therapy could
not be calculated because of too few included 
studies.
H Ho os sp pi it ta al li iz za at ti io on n
Summary RR of hospitalization in two RCTS [12,
15] was 0.61 with a 95% CI of 0.44-0.86, a signifi-
cant RR (p = 0.005, Figure 4 A). The Cochrane Q test
for heterogeneity indicated that the studies are
homogeneous (p = 0.31, Figure 4 B) and could be
combined but because of few included studies, the
random effects for individual and summary of RR
was applied. Regression of normalized effect vs. pre-
cision for all included studies in the outcome of hos-
pitalization among IFX vs. placebo therapy could
not be calculated because of too few included 
studies.
I In nf fe ec ct ti io ou us s   c co om mp pl li ic ca at ti io on n
Summary OR of infectious complication in nine
observational studies [9-11, 17-22] was 1.56 with
a 95%  CI  of  0.71-3.44,  a non-significant  OR 
(p = 0.27, Figure 5 A-a). The Cochrane Q test for het-
erogeneity indicated that the studies are hetero-
geneous (p < 0.0001, Figure 5 A-b) and could not
be combined; thus the random effects for individ-
ual and summary of OR was applied. Regression of
normalized effect vs. precision for all included stud-
ies  in  the  outcome  of  infectious  complication
among IFX vs. placebo therapy was –1.08 (95% CI =
–6.02 to 3.86, p = 0.62) and Kendall’s test on stan-
dardized effect vs. variance indicated tau = –0.11, 
p = 0.61 (Figure 5 C).
Summary RR of infectious complication in two
clinical trials [15, 16] was 0.37 with a 95% CI of
0.09-1.44, a non-significant RR (p = 0.15, Figure 
5 B-a). The Cochrane Q test for heterogeneity indi-
cated that the studies are not heterogeneous 
(p = 0.9013, Figure 5 B-b) and could be combined
but because of few included studies, the random
effects for individual and summary of RR was
applied. Regression of normalized effect vs. pre-
cision for all included studies in the outcome of
infectious complication among IFX vs. placebo
therapy could not be calculated because of too
few included studies.
R Re ef fe er re en nc ce es s R Ra an nd do om mi iz za at ti io on n B Bl li in nd di in ng g W Wi it th hd dr ra aw wa al ls s   a an nd d   d dr ro op po ou ut ts s T To ot ta al l   J Ja ad da ad d   s sc co or re e
Gustavsson et al.  10 1 2
Jarnerot et al.  22 1 5
Sandborn et al. 11 1 3
T Ta ab bl le e   I I. . Jadad score of clinical trials
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E Ea ar rl ly y   p po os st t- -o op pe er ra at ti iv ve e   c co om mp pl li ic ca at ti io on n
Summary OR of early post-operative complica-
tion in two observational studies [17, 22] was 2.11
with  a 95%  CI  of  1.02-4.36,  a significant  OR 
(p = 0.04, Figure 6 A). The Cochrane Q test for het-
erogeneity indicated that the studies are not het-
erogeneous (p = 0.34, Figure 6 B) and could be com-
bined but because of few included studies, the
random effects for individual and summary of OR
was applied. Regression of normalized effect vs. pre-
cision for all included studies in the outcome of ear-
ly post-operative complication among IFX vs. place-
bo therapy could not be calculated because of too
few included studies.
L La at te e   p po os st t- -o op pe er ra at ti iv ve e   c co om mp pl li ic ca at ti io on n
Summary OR of late post-operative complication
in two observational studies [17, 22] was 1.57 with
a 95% CI of 0.8-3.06, a non-significant OR (p = 0.19,
Figure 7 A). The Cochrane Q test for heterogeneity
indicated that the studies are not heterogeneous
(p = 0.49, Figure 7 B) and could be combined but
because of few included studies, the random effects
for individual and summary of OR was applied.
R Re ef fe er re en nc ce es s T Ty yp pe e   o of f   s st tu ud dy y I In nc cl lu us si io on n   c cr ri it te er ri ia a                     N Nu um mb be er r   o of f   p pa at ti ie en nt ts s C Co on nc co om mi it ta an nt t    D Du ur ra at ti io on n   o of f    D Do os sa ag ge e   
R Re ec ce ei iv ve ed d D Di id d   n no ot t
t th he er ra ap py y I IF FX X   t th he er ra ap py y o of f   I IF FX X
I IF FX X r re ec ce ei iv ve e   
I IF FX X
Ferrante  Cohort UC 141 AZA, 6-MP,   12 weeks prior NA
et al. [9] IBD type unclassified
22 119
MTX, CsA, CS to primary
Gustavsson  RCT Steroid refractory  45 Immunomodulator,  Data not  5 mg/kg
et al. [15] UC
24 21
5-ASA available
Mor Case matched  UC, indeterminate  92 CS, CsA, 6-MP More than  NA
et al. [22] retrospective  colitis
46 46 matched
16 week 
study preoperatively
Kunitake  Cohort UC, CD,  413 CS, AZA, 6-MP 12 weeks  5 or 10 
et al. [10] indeterminate colitis
101 312
before surgery mg/kg
Marchal  Cohort CD 79 AZA, CS, ASA,  Data not  5 mg/kg
et al. [17]
40 39
MTX, antibiotic,  available
budesonide
Bordeianou  Cohort Ulcerative or  171 CS, 6-MP,  Within 12 weeks  NA
et al. [11] indeterminate colitis
44 127
imuran, AZA prior to surgery
Schluender  Cohort UC 151 CS, 6-MP,  Median of two  NA
et al. [18]
17 134
6-TG, CsA (range 1–12) 
months 
before surgery
Colombel Cohort CD 270 CS,  Within 8 weeks 5 mg/kg
et al. [19]
52 218
immunomodulator before surgery
or within 
30 days 
after surgery
Appau  Cohort CD 389 ASA, AZA, MTX,  Data  NA
et al. [20]
60 329
6-MP, CS not available
Selvasekar  Cohort Chronic UC 301 CS, AZA, 5-ASA 2-6 months  NA
et al. [21]
47 254
prior to the 
surgery
Jarnerot  RCT UC 45 CS 3 months 4-5 mg/kg
et al. [16]
24 21
Sandborn  RCT UC 728 CS, AZA,  54 weeks 5 or 10 
et al. [12]
484 244
6-MP, 5-ASA mg/kg
T Ta ab bl le e   I II I. .   Characteristics of studies included in the meta-analysis
RCT – randomized controlled trial, UC – ulcerative colitis, CD – Crohn’s disease, 5-ASA – 5-aminosalicylates, CS – corticosteroids, AZA – aza-
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Regression of normalized effect vs. precision for all
included studies in the outcome of late post-oper-
ative complication among IFX vs. placebo therapy
could not be calculated because of too few includ-
ed studies.
P Po os st t- -o op pe er ra at ti iv ve e   s si id de e   e ef ff fe ec ct ts s   i in n   p pa at ti ie en nt ts s   w wi it th h
i in nf fl la am mm ma at to or ry y   b bo ow we el l   d di is se ea as se e   w wh ho o   t to oo ok k
i in nf fl li ix xi im ma ab b   p pr re e- -o op pe er ra at ti iv ve el ly y   a an nd d   t th ho os se e   w wh ho o   
d di id d   n no ot t   
A An na as st to om mo ot ti ic c   l le ea ak k
Summary OR for anastomotic leak in seven
observational studies [9-11, 17, 20-22] was 1.71 with
a 95% CI of 1.02-2.87, a significant OR (p = 0.05)
(Table III). The Cochrane Q test for heterogeneity
indicated that the studies are not heterogeneous
(p = 0.07) and could be combined; thus the fixed
effects for individual and summary of OR was
applied. Regression of normalized effect vs. preci-
sion for all included studies in the outcome of anas-
tomotic leak among IFX vs. placebo therapy was –
1.69 (95% CI = –5.29 to 1.92, p = 0.28) and Kendall’s
test on standardized effect vs. variance indicated
tau = –0.43 (p = 0.14). 
P Pe el lv vi ic c   a ab bs sc ce es ss s
Summary OR for pelvic abscess in two observa-
tional studies [9, 21] was 1.09 with a 95% CI of 
0.17-6.93, a non-significant OR (p = 0.93). The
Cochrane Q test for heterogeneity indicated that
the studies are not heterogeneous (p = 0.15) and
could be combined but because of few included
studies the random effects for individual and sum-
mary of OR was applied. Regression of normalized
effect vs. precision for all included studies in the
outcome of pelvic abscess among IFX vs. placebo
therapy could not be calculated because of too few
included studies.
P Po ou uc ch h- -r re el la at te ed d   c co om mp pl li ic ca at ti io on ns s
Summary OR for pouch-related complications in
three observational studies [9, 21, 22] was 2.06 with
a 95% CI of 1.16-3.66, a significant OR (p = 0.023).
The Cochrane Q test for heterogeneity indicated
that the studies are not heterogeneous (p = 0.054)
and could be combined; thus the fixed effects for
individual and summary of OR was applied. Regres-
sion of normalized effect vs. precision for all includ-
F Fi ig gu ur re e   1 1. .   Flow diagram of the study selection process
2 articles excluded because 
of duplication or not meeting 
the criteria
630 articles excluded on
basis of irrelevant title 
and abstract
12 articles included and
meta-analysed
644 potentially relevant articles from
electronic search
113 from PubMed
483 from Scopus
51 from Web of Science
17 from Cochrane Library
14 articles
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ed studies for pouch-related complication among
IFX vs. placebo therapy could not be calculated
because of too few included studies. 
W Wo ou un nd d   i in nf fe ec ct ti io on n
Summary OR for wound infection in three obser-
vational studies [9, 17, 21] was 1.96 with a 95% CI
of 0.84-4.62, a non-significant OR (p = 0.19). The
Cochrane Q test for heterogeneity indicated that
the studies are not heterogeneous (p = 0.29) and
could be combined; thus the fixed effects for indi-
vidual and summary of OR was applied. Regression
of normalized effect vs. precision for all included
studies in the outcome of wound infection among
IFX vs. placebo therapy could not be calculated
because of too few included studies.
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O Ot th he er r   i in nf fe ec ct ti io on ns s
Summary OR for other infections in four observa  -
tional studies [9, 10, 17, 21] was 1.53 with a 95% CI
of 0.41-5.67, a non-significant OR (p = 0.53). The
Cochrane Q test for heterogeneity indicated that
the studies are heterogeneous (p = 0.005) and
could not be combined; thus the random effects
for individual and summary of OR was applied.
Regression of normalized effect vs. precision for all
included studies in the outcome of other infections
among IFX vs. placebo therapy was –0.65 (95% CI
= –13.35 to 12.05, p = 0.85) and Kendall’s test on
standardized effect vs. variance indicated tau = 0,
p = 0.75. 
Summary RR for other infections in two clinical
trials [15, 16] was 1.06 with a 95% CI of 0.16-6.87,
a non-significant RR (p = 0.95). The Cochrane Q test
for heterogeneity indicated that the studies are not
het-
ero-
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geneous (p = 0.48) and could be combined but
because of few included studies, the random effects
for individual and summary of OR was applied.
Regression of normalized effect vs. precision for all
included studies in the outcome of other infections
among IFX vs. placebo therapy could not be calcu-
lated because of too few included studies.
S Sm ma al ll l   i in nt te es st ti in na al l   o ob bs st tr ru uc ct ti io on n
Summary OR for small intestinal obstruction in
two observational studies [17, 22] was 0.44 with
a 95%  CI  of  0.12-1.64,  a non-significant  OR 
(p = 0.22). The Cochrane Q test for heterogeneity
indicated that the studies are not heterogeneous
(p = 0.83) and could be combined but because of
few included studies the random effects for indi-
vidual and summary of OR was applied. Regression
of normalized effect vs. precision for all included
studies in the outcome of small intestinal obstruc-
tion among IFX vs. placebo therapy could not be
calculated because of too few included studies.
G GI I   c co om mp pl li ic ca at ti io on ns s   ( (n na au us se ea a, ,   v vo om mi it ti in ng g, ,   d dy ys sp pe ep ps si ia a, ,
a an nd d   r re ef fl lu ux x) )
Summary RR for GI complications in two clinical
trials [15, 16] was 4.17 with a 95% CI of 0.48-35.94,
a non-significant RR (p = 0.19). The Cochrane Q test
for heterogeneity indicated that the studies are not
heterogeneous (p = 0.96) and could be combined
but because of few included studies, the random
effects for individual and summary of RR was applied.
Regression of normalized effect vs. precision for all
included studies in the outcome of GI complications
among IFX vs. placebo therapy could not be calcu-
lated because of too few included studies.
S Se ep ps si is s
Summary OR for sepsis in four observational
studies [17, 19, 20, 22] was 1.85 with a 95% CI of
1.15-2.97, a significant OR (p = 0.02). The Cochrane
Q test for heterogeneity indicated that the studies
are not heterogeneous (p = 0.054) and could be
combined; thus the fixed effects for individual and
summary of OR was applied. Regression of nor-
malized effect vs. precision for all included studies
in the outcome of sepsis among IFX vs. placebo
therapy was 1.78 (95% CI = –5.2 to 8.8, p = 0.39)
and Kendall’s test on standardized effect vs. vari-
ance indicated tau = 0, p = 0.75.
P Po os st t- -o op pe er ra at ti iv ve e   h ha ae em mo or rr rh ha ag ge e   
Summary OR for post-operative haemorrhage
in two observational studies [10, 22] was 2.24 with
a 95%  CI  of  0.42-11.85,  a non-significant  OR 
(p = 0.34). The Cochrane Q test for heterogeneity
indicated that the studies are not heterogeneous
(p = 0.67) and could be combined but because of
few included studies the random effects for indi-
vidual and summary of OR was applied. Regres-
sion of normalized effect vs. precision for all
included studies in the outcome of postoperative
haemorrhage among IFX vs. placebo therapy could
not be calculated because of too few included
studies.
S Si id de e   e ef ff fe ec ct ts s O OR R/ /R RR R   c co om mb bi in ne ed d    C CI I V Va al lu ue e   o of f   p p V Va al lu ue e   o of f   p p P Pu ub bl li ic ca at ti io on n   
m me et ta a- -a an na al ly ys si is s f fo or r   O OR R/ /R RR R f fo or r   h he et te er ro og ge en ne ei it ty y b bi ia as s
Anastomotic leak OR: 1.71  1.02-2.87 0.05 0.07 No
Pelvic abscess OR: 1.09  0.17-6.93 0.93 0.15 NA
Pouch-related complication OR: 2.06  1.16-3.66 0.023 0.054 NA
Wound infection OR: 1.96 0.84-4.62 0.19 0.29 NA
Other infections OR: 1.53 0.41-5.67 0.53 0.005 No
RR: 1.06 0.16-6.87 0.95 0.48 NA
Small intestinal obstruction OR: 0.44  0.12-1.64 0.22 0.83 NA
GI complications RR: 4.17  0.48-35.94 0.19 0.96 NA
Sepsis OR: 1.85  1.15-2.97 0.02 0.054 No
Postoperative haemorrhage  OR: 2.24  0.42-11.85 0.34 0.67 NA
Thrombotic event 4.56  1.12-18.53 0.03 0.94 NA
Ileus OR: 0.95  0.19-4.68 0.95 0.42 NA
Wound failure 1.27  0.15-10.55 0.82 0.78 NA
Intra-abdominal abscess 1.85  0.79-4.3 0.16 0.5 NA
T Ta ab bl le e   I II II I. .   Post-operative side effects in patients with IBD who took IFX before operation and those who did not 
NA – not applicable
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T Th hr ro om mb bo ot ti ic c   e ev ve en nt t
Summary OR for thrombotic event in two stud-
ies [10, 22] was 4.56 with a 95% CI of 1.12-18.53,
a significant OR (p = 0.03). The Cochrane Q test for
heterogeneity indicated that the studies are not
heterogeneous (p = 0.94) and could be combined
but because of few included studies, the random
effects for individual and summary of OR was
applied. Regression of normalized effect vs. preci-
sion for all included studies in the outcome of
thrombotic event among IFX vs. placebo therapy
could not be calculated because of too few includ-
ed studies.
I Il le eu us s
Summary OR for ileus in two observational
studies [17, 22] was 0.95 with a 95% CI of 0.19-
4.68, a non-significant OR (p = 0.95). The Cochrane
Q test for heterogeneity indicated that the stud-
ies are not heterogeneous (p = 0.42) and could be
combined but because of few included studies,
the random effects for individual and summary of
OR was applied. Regression of normalized effect
vs. precision for all included studies in the out-
come of ileus among IFX vs. placebo therapy could
not be calculated because of too few included
studies.
W Wo ou un nd d   f fa ai il lu ur re e
Summary OR for wound failure in two studies
[17, 20] was 1.27 with a 95% CI of 0.15-10.55, a non-
significant OR (p = 0.82). The Cochrane Q test for
heterogeneity indicated that the studies are not
heterogeneous (p = 0.78) and could be combined
but because of few included studies, the random
effects for individual and summary of OR was
applied. Regression of normalized effect vs. preci-
sion for all included studies in the outcome of
wound failure among IFX vs. placebo therapy could
not be calculated because of too few included
studies.
I In nt tr ra a- -a ab bd do om mi in na al l   a ab bs sc ce es ss s
Summary OR for intra-abdominal abscess in
three studies [11, 17, 20] was 1.85 with a 95% CI of
0.79-4.3, a non-significant OR (p = 0.16). The
Cochrane Q test for heterogeneity indicated that
the studies are not heterogeneous (p = 0.5) and
could be combined but because of few included
studies, the random effects for individual and sum-
mary of OR was applied. Regression of normalized
effect vs. precision for all included studies in the
outcome of intra-abdominal abscess among IFX
vs.  placebo  therapy  could  not  be  calculated
because of too few included studies.
Discussion
The present meta-analysis found that there is
no significant difference in the rate of colectomy
in the patients with UC who received IFX in com-
parison to the patients who did not receive IFX.
Mortality was not significantly different between
the two groups either. However, the level of post-
operative hospitalization in patients who were
under IFX therapy was lower than in the control
group.
There has been no meta-analysis addressing the
effect of IFX therapy on the rate of colectomy.
Wihelm et al. mentioned the efficacy of IFX in their
review [23]. However, among the articles included
in that review, only Jarnerot et al. studied the effect
of IFX on the rate of colectomy and found that 21%
of the IFX group required colectomy within the first
90 days after treatment in comparison to 67% in
the placebo group (p = 0.017) [16]. Gustavsson 
et al. found that colectomy in short term (3 months)
and also long term (3 years) is reduced in the IFX
group with a colectomy frequency of 50% as com-
pared with 76% in the placebo group in 3 years [15].
However, most of the colectomies were performed
during the first 3 months. In the cohort of Schlu-
ender et al., two out of 17 patients in the IFX group
and 37 out of 134 patients in the non-IFX group
underwent colectomy [18]. The RCT of Sandborn et
al. showed that patients with moderate to severe
UC treated with IFX were less likely to undergo
colectomy during 54 weeks than those receiving
placebo despite concurrent medication. However,
that trial due to the long period of follow-up was
limited by the colectomy follow-up [12]. Several
uncontrolled studies showed that the rate of colec-
tomy in patients under IFX therapy is less than 50%
[24-27]. However, those studies had different dura-
tion of follow-up and no control groups. This indi-
cates that for more accurate results on the effica-
cy of IFX in the rate of colectomy, more controlled
trials should be performed.
This meta-analysis also found that overall early
post-operative complications were more frequent
among patients who received IFX pre-operatively.
However, overall infectious complications in clini-
cal trials and also observational studies were not
significantly different between patients who were
treated with IFX and those who were not. Among
side effects, anastomotic leak, pouch-related com-
plications, sepsis and particularly thrombotic events
were significantly more common in patients who
were treated with IFX pre-operatively. There is
a meta-analysis on the effect of IFX on short-term
post-operative complications in patients with UC
demonstrating  that  short-term  complications
increase with the use of IFX but infectious compli-
cations and non-infectious complications do not
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significantly increase [13]. Selvasekar et al. found
a significantly increased risk for post-operative
pouch-specific and infectious complications in 47
UC patients who had been treated with IFX before
ileal pouch anal anastomosis compared to 254 con-
trol patients. Confounding factors such as age,
severity of colitis, concomitant use of immunomod-
ulatory drugs, and corticosteroids were adjusted
and still IFX remained an independent predictor of
infections [21]. Schluender et al. did not find any
significant difference in overall post-operative or
infectious complications between 17 UC patients
who had been treated with IFX before surgery and
134 control patients [18]. Mor et al. found that the
covariate adjusted odds ratio of early complication
for 85 patients with UC or indeterminate colitis in
the IFX group was 3.54 times higher than that of
523 patients in the control group [22]. Kunitake et
al., who evaluated patients with UC, CD, and inde-
terminate colitis, did not find any significant dif-
ference in development of post-operative infectious
complications in 101 patients treated with IFX and
312 patients not treated [10].
Appau et al. found that pre-surgical treatment
with IFX in patients with CD is associated with
increased post-operative sepsis, abscess and re-
admissions [20]. However, Marchal et al. showed
that IFX therapy in patients with CD did not increase
the rate of post-operative complications in com-
parison to patients who did not take IFX [17].
To overcome heterogeneity in our meta-analy-
sis, we pooled studies that assessed UC and CD for
post-operative complications. However, the rate of
colectomy was only analysed in the patients with
UC because CD patients rarely undergo isolated
colectomy. Combining the patients with UC and the
patients with CD in the analyses may have an influ-
ence on the results because of their different clin-
ical course, but there is evidence [10] that the dif-
ference in the rate of IFX-associated complications
between UC and CD patients is not significant. We
analysed clinical trials and observational studies
separately. Although observational studies are more
realistic, bias is more frequent. On the other hand,
the internal validity in RCTs is higher and the exter-
nal validity is lower. However, we did not find a large
difference in the results of observational studies vs.
clinical trials. In the mortality and infectious com-
plications, the results were opposite. In the obser-
vational studies, mortality and infectious compli-
cations were more frequent in the patients under
IFX therapy. However, the meta-analysis of both
types showed that the differences are not signifi-
cant in these two variables.  
In the included studies, there were some kinds
of bias such as unclear duration of IFX therapy
and/or concomitant therapies and/or the dosage
of IFX that inevitably might affect the results of the
meta-analysis. For instance, in some studies, such
as those of Mor et al. [22], Marchal et al. [17], and
Selvasekar et al. [21], all the patients who had ever
been treated with IFX were included in the IFX
group regardless of the duration of treatment
before surgery. Concomitant drugs may also influ-
ence the post-surgical complications such as seri-
ous infection seen in CD patients who had been
treated with IFX in combination with corticosteroids
or narcotic analgesics [28]. In fact, in the majority
of the studies that assessed the safety of anti-TNF
drugs, the majority of patients were receiving con-
comitant immunomodulators or corticosteroids that
may have increased the risk of opportunistic infec-
tion [29]. Moreover, Ferrante et al. found that
a moderate-to-high dose of corticosteroids but not
IFX is associated with short-term post-operative
infectious complications [9]. It is notable that micro-
bial infection has a fundamental role in pathogen-
esis of IBD that cannot be neglected and thus most
current management protocols for IBD [30, 31] and
other forms of colitis [32] suggest the use of antibi-
otics. Of course, the matter of cytokines and inflam-
mation is too complex. For instance, production of
cytokines in chronic inflammation prevents further
enhancement of cytokine synthesis triggered by
surgery and other normal physiological responses
may play roles [33].
Despite some recorded heterogeneity in our
meta-analysis, no publication bias was found in
the analysis. Funnel plot analysis was used as
a publication bias indicator. Funnel plots, that is
simple scatter plots of the trials' effect, estimate
their sample size in detecting any bias in the
meta-analysis. The funnel plot is based on the fact
that precision in estimating the underlying treat-
ment effect will increase as the sample size of
component studies increases. Results from small
studies will scatter widely at the bottom of the
graph. The spread will narrow as precision increas-
es among larger studies. In the absence of bias,
the plot should thus resemble a symmetrical
inverted funnel [34]. 
In conclusion, this meta-analysis revealed that
although IFX use neither decreases the rate of
colectomy nor increases the rate of infectious com-
plications in IBD patients, thrombotic events, ileal
pouch complications, sepsis and anastomotic leaks
are the complications that were increased in the
patients who used IFX. On the other hand, post-
operative hospitalization is less frequent in the
patients under IFX therapy. The patients with IBD
who are under IFX therapy are most of the time
refractive to other therapies and their disease is in
a severe stage. Thus it is possible that the post-
operational complications in the IFX group are asso-
ciated with the severity of the disease, and while
the studies that are included in the meta-analysis
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are heterogeneous, we cannot consider this as an
exclusive result of IFX.
Further clinical trials on the efficacy of IFX in
patients with CD and on different types of surgery
in patients with IBD are needed for more accurate
results.
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